Liquidia Attacks UTC’s Tyvaso Drug Patent at Bench Trial Opening

United Therapeutics Corp. fought to save a valuable patent from being invalidated in court, telling a federal judge it pioneered the first effective treatment for high blood pressure related to lung scarring with its drug Tyvaso.

During opening arguments at a bench trial in UTC’s infringement suit against Liquidia Corp. Monday in the US District Court for the District of Delaware, UTC set the stage for countering Liquidia Corp.'s attacks on UTC’s US Patent No. 11,826,327, which covers the use of inhaled treprostinil—marketed as Tyvaso—to treat pulmonary hypertension associated with interstitial lung disease. Liquidia Corp. argued doctors were already ...